Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of ASC09F in Healthy Subjects
NCT04547894Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Nov 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TMC-310911 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Ascletis Pharma Inc. Primary endpoints: Area Under the Curve of ASC09F at Day 10 and Maximum Plasma Concentration of ASC09F at Day 10. Started Nov 2020; status: completed.
02
Drugs
TMC-310911
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04547894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547894.